Integrating new and “old” cellular therapies in the evolving landscape of relapsed or refractory large B-cell lymphoma
Enrico Amaducci, Michele Clerico, Davide Camoirano, Claudia Marinucci, Luisa Giaccone, Irene Dogliotti, Michele Dicataldo, Mattia D’Agostino, Benedetto Bruno, Federica Cavallo · 2026
Read Integrating new and “old” cellular therapies in the evolving landscape of relapsed or refractory large B-cell lymphoma by Enrico Amaducci, Michele Clerico, Davide Camoirano, Claudia Marinucci, Luisa Giaccone, Irene Dogliotti, Michele Dicataldo, Mattia D’Agostino, Benedetto Bruno, Federica Cavallo (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13617608.txt.
Description
Amaducci and co-authors review how cell based treatments fit together for a fast growing blood cancer that has come back or stopped responding. New engineered cell therapy is now standard for early relapse, based on two large trials. Their review, published in 2026, also covers older transplant care.
Salvage drug care plus a patient's own stem cell transplant is now saved for late relapse. Donor transplants remain a narrow option for fit patients with no other choice. The authors use a hard case, relapse in the brain and spine, to show how choices stack up. Next steps include cells built to hit two targets at once. New designs aim to beat the ways cancer cells escape such therapy.
Catalog record
| CREATOR | Enrico Amaducci, Michele Clerico, Davide Camoirano, Claudia Marinucci, Luisa Giaccone, Irene Dogliotti, Michele Dicataldo, Mattia D’Agostino, Benedetto Bruno, Federica Cavallo |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 37 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |